Johnson & Johnson has tentatively agreed to pay about $700M to resolve an investigation by more than 40 U.S. states of claims that it wrongfully marketed its talc-based baby powder by not warning about possible health risks, Jef Feeley of Bloomberg reports, citing people familiar with the deal.The settlement would avert potential lawsuits alleging that J&J hid any links between the talc in its powder and various cancers, sources told Bloomberg. The people added that J&J and representatives for state attorneys general are still figuring out the specific terms of the accord but have reached an agreement on the total amount.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on JNJ:
- Illumina expands collaboration with Janssen R&D
- Mersana Therapeutics announces business updates, expected 2024 milestones
- The biopharmaceuticals stocks to own in 2024, according to BofA
- Elektrofi, Janssen Biotech enter collaboration, license agreement
- Neumora Therapeutics price target raised to $20 from $18 at BofA